Evaluating triptorelin as a treatment option for breast cancer.

Evaluating triptorelin as a treatment option for breast cancer. Expert Opin Pharmacother. 2019 Sep 09;:1-10 Authors: Ferraro E, Trapani D, Marrucci E, Curigliano G Abstract Introduction: Triptorelin is a luteinizing hormone-releasing hormone analog (LH-RHa) inducing ovarian function suppression (OFS). It is approved by FDA and EMA in association with tamoxifen or aromatase inhibitor (AI) and with fulvestrant and palbociclib in premenopausal women with hormone receptor (HR)-positive breast cancer. Its potential role to preserve ovarian function during chemotherapy has also been recently clarified. Areas covered: Several studies have investigated the role of adding OFS to tamoxifen and aromatase inhibitors as adjuvant treatment in early breast cancer. The addition of triptorelin is not free from adverse events as the combination with tamoxifen and exemestane resulted in an increase of endocrine-deprivation symptoms. Clinical trials have explored the combination of LH-RHa with chemotherapy in fertility preservation, demonstrating no detrimental effect on patients' oncological outcome. This is all discussed in this evaluation. Expert opinion: Triptorelin represents a standard-of-care in premenopausal women with HR-positive breast cancer and in some cases of male breast cancer. In the adjuvant setting, a personalized approach is required to combine LH-RHa with the right partner considering the risk of recurrence and the toxicity profile. LH-RHa may be offered ...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Related Links:

ConclusionsOur findings show thatBRCA1/2 mutations account for one in four cases of hereditary breast/ovarian cancer, one in five cases of male breast cancer, and one in eight cases of early-onset breast cancer in Pakistan. Our study suggests genetic testing of an extended panel of 21 recurrentBRCA1/2 mutations for appropriately selected patients and their families in Pakistan.
Source: Hereditary Cancer in Clinical Practice - Category: Cancer & Oncology Source Type: research
Pathogenic variants (ie, mutations) in the breast cancer susceptibility 1 and 2 (BRCA1/2) genes are associated with a high risk of ovarian and female breast cancer as well as, particularly for BRCA2, elevated risks of male breast cancer, aggressive prostate cancer, and pancreatic cancer. The risks of ovarian cancer and breast cancer are as high as 45% and 70%, respectively. The detection of a BRCA1/2 pathogenic variant can significantly alter medical management (by early detection or risk reduction strategies) and improve outcomes.
Source: JAMA - Category: General Medicine Source Type: research
In this study, we aimed to investigate the mutation spectrum of BRCA1 and BRCA2 genes in hereditary breast/ovarian cancer (HBOC) families from the Aures region (eastern Algeria). High risk breast/ovarian cancer families were selected from overall 1162 consecutive patients collected from cancer registry of anticancer center of Batna. Breast cancers were diagnosed between 2011 and 2015. Recurrent mutations on BRCA1 and BRCA2 previously found in Algerian patients were screened using PCR-direct sequencing in 113 HBOC families. In addition, for the first time in Algeria, HBOC patients were analyzed by NGS using a cancer panel o...
Source: Pathology Oncology Research - Category: Pathology Authors: Tags: Pathol Oncol Res Source Type: research
ConclusionIn men, we observed a lowered all-cause mortality and an excess of stomach cancer in workshop workers. In women, increased risks of overall cancer, lung cancer and ovarian cancer was seen. An increased risk of bladder cancer and a lowered incidence of brain cancer was observed among female cleaners.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
Condition:   HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer Interventions:   Drug: PF-06873600;   Drug: Endocrine Therapy 1;   Drug: Endocrine Therapy 2 Sponsor:   Pfizer Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Authors: Cao A, Huang L, Shao Z Abstract Approximately 5-10% of breast cancer is considered to be hereditary. Familial breast cancers exhibit a dominant hereditary pattern, which typically have an early age of onset and are accompanied by symptoms of ovarian cancer, bilateral breast cancer, or male breast cancer. BRCA gene mutation carriers should be regarded as high-risk groups for breast cancer, which necessitates early examination of breast cancer. Studies have built up kinds of predictive models and recommended that female BRCA mutation carriers should receive breast self-test training and take monthly breast s...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
In Stories of Hope, we regularly publish the stories of people who have a positive message to share, whether their cancer diagnosis was just recently, or long ago. Our featured survivors share words of inspiration, wisdom, hope, and support in these stories about how their lives have been changed by cancer. Our editors have chosen 10 of the most inspirational stories of 2016. For many who are facing a cancer diagnosis, or any other illness or hardship, hearing from others who've been through one already can be a great source of comfort and support. We hope you will find inspiration in these stories of cancer survivors. &nb...
Source: American Cancer Society :: News and Features - Category: Cancer & Oncology Tags: Coping with Cancer Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Drugs & Pharmacology | Hormones | Male Breast Cancer | Ovarian Cancer | Ovaries | Reproduction Medicine | Study | Tamoxifen | Toxicology | Women